

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6346635

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE UNVERISTY COURT OF THE UNIVERSITY OF ABERDEEN	10/06/2020
RECEIVING PARTY DATA	
Name:	ELASMOGEN LIMITED
Street Address:	LIBERTY BUILDING
Internal Address:	FORESTERHILL
City:	ABERDEEN
State/Country:	UNITED KINGDOM
Postal Code:	AB25 2ZP
PROPERTY NUMBERS Total: 6	
Property Type	Number
Patent Number:	9475870
Patent Number:	10287341
Application Number:	16297544
Patent Number:	10202438
Application Number:	16271959
Patent Number:	10472410
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	scott.lee@arrigo.us
Correspondent Name:	ARRIGO, LEE, GUTTMAN & MOUTA-BELLUM LLP
Address Line 1:	2200 PENNSYLVANIA AVE NW
Address Line 2:	STE 4E
Address Line 4:	WASHINGTON, D.C. 20037-1748
ATTORNEY DOCKET NUMBER:	P52896US3
NAME OF SUBMITTER:	SCOTT M. K. LEE
SIGNATURE:	/Scott M. K. Lee/
DATE SIGNED:	10/13/2020

Total Attachments: 2

source=signed assignation doc for US Div UoA Elasmogen Oct 2020#page1.tif

source=signed assignation doc for US Div UoA Elasmogen Oct 2020#page2.tif

ASSIGNMENT

WHEREAS I/We, THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, a charity registered in Scotland SC013683 and having its principal place of business at University Office, King's College, Regent Walk, Aberdeen, AB24 3FX (hereinafter referred to as "Assignor") is/was the owner by Assignment of the following United States patents and United States patent applications:

United States Patent No. 9,475,870, issued October 25, 2016, from Application No. 15/005,463, filed January 25, 2016, and titled SINGLE DOMAIN BINDING MOLECULE;

United States Patent No. 10,287,341, issued May 14, 2019, from Application No. 15/273,197, filed September 22, 2016, and titled SINGLE DOMAIN BINDING MOLECULE;

United States Patent Application No. 16/297,544, filed March 8, 2019, and titled SINGLE DOMAIN BINDING MOLECULE;

United States Patent No. 10,202,438, issued February 12, 2019, from Application No. 14/786,074, filed April 23, 2014, as International Application No. PCT/EP2014/058251, and titled SYNTHETIC LIBRARY OF SPECIFIC BINDING MOLECULES;

United States Patent Application No. 16/271,959, filed February 11, 2019, and titled SYNTHETIC LIBRARY OF SPECIFIC BINDING MOLECULES; and

United States Patent No. 10,472,410, issued November 12, 2019, from Application No. 14/785,975, filed April 23, 2014, as International Application No. PCT/EP2014/058276, and titled ISOLATION OF THERAPEUTIC TARGET SPECIFIC VNAR DOMAINS TO ICOSL (together the "listed patents and patent applications");

WHEREAS ELASMOGEN LIMITED, a company incorporated and registered in Scotland with company number SC467513 whose registered office is at Liberty Building, Foresterhill, Aberdeen, AB25 2ZP (hereinafter referred to as "Assignee"), is/was desirous of acquiring an interest in the listed patents and patent applications, and the inventions disclosed therein;



NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from the Assignee(s) is hereby acknowledged, I/We, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee(s), its/their lawful successors and assigns, my/our entire right, title, and interest in and to listed patents and patent applications, and all divisions, and continuations thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues thereof, and all rights to claim priority on the basis of these applications; and I/We hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue all Letters Patent for this invention to the Assignee(s), its/their successors and assigns, in accordance with the terms of this Assignment;

AND, I/WE HEREBY covenant that I/We have the full right to convey the interest assigned by this Assignment, and I/We have not executed and will not execute any agreement in conflict with this Assignment;

AND, I/WE HEREBY further covenant and agree that I/We will, without further consideration, communicate with the Assignee(s), its/their successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee(s), its/their successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid the Assignee(s), its/their successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any other country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee(s), its/their successors and assigns;

AND, the Assignee hereby agree that it is/will be required to comply with certain obligations to which the Assignor is/was subject, as set forth in the "ASSIGNATION OF PATENTS between The University of Aberdeen and Elasmogen Limited 9th May 2019".

IN TESTIMONY WHEREOF, I/We have hereunto set my/our hands.

Name:	THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
(Assignor)	
Address:	University Office, King's College, Regent Walk, Aberdeen, AB24 3FX UK
Signature	
Title:	Dr Elizabeth Ratray, Director Research & Innovation
Date:	6th October 2020
Name:	ELASMOGEN LIMITED
(Assignee)	
Address:	Liberty Building, Foresterhill, Aberdeen, AB25 2ZP, UK
Signature:	
Title:	CTO DIRECTOR
Date:	9 th OCT 2020